[1]
|
P. M. Irving, K. J. Pasi and D. S. Rampton, “Thrombosis and Inflammatory Bowel Disease,” Clinical Gastroenterology and Hepatology, Vol. 3, No. 7, 2005, pp. 617-628. http://dx.doi.org/10.1016/S1542-3565(05)00154-0
|
[2]
|
D. Silvio, C. de la Motte and C. Fiocchi, “Platelets in Inflammatory Bowel Disease: Clinical, Pathogenic, and Therapeutic Implications,” American Journal of Gastroenterology, Vol. 99, No. 5, 2004, pp. 938-945. http://dx.doi.org/10.1111/j.1572-0241.2004.04129.x
|
[3]
|
M. Griesshammer, M. Bangerter, T. Sauer, R. Wennauer, L. Bergmann and H. Heimpel, “Aetiology and Clinical Significance of Thrombocytosis: Analysis of 732 Patients with an Elevated Platelet Count,” Journal of Internal Medicine, Vol. 245, No. 3, 1999, pp. 295-300. http://dx.doi.org/10.1046/j.1365-2796.1999.00452.x
|
[4]
|
A. I. Schafer, “Thrombocytosis,” New England Journal of Medicine, Vol. 350, No. 12, 2004, pp. 1211-1219. http://dx.doi.org/10.1056/NEJMra035363
|
[5]
|
A. M. Vanucchi and T. Barbui, “Thrombocytosis and Thrombosis. Hematology, Vol. 2007, No. 1, 2007, pp. 363-370. http://dx.doi.org/10.1182/asheducation-2007.1.363
|
[6]
|
B. Anger, J. W. Janssen, H. Schrezenmeier, R. Hehlmann, H. Heimpel and C. R. Bartram, “Clonal Analysis of Chronic Myeloproliferative Disorders Using X-Linked DNA Polymorphisms,” Leukemia, Vol. 4, No. 4, 1990, pp. 258-261.
|
[7]
|
Y. L. Wang, K. Vandris, A. V. Jones, N. C. Cross, P. Christos, F. Adriano and R. T. Silver, “JAK2 Mutations Are Present in All Cases of Polycythemia Vera,” Leukemia, Vol. 22, No. 6, 2008, p. 1289. http://dx.doi.org/10.1038/sj.leu.2405047
|
[8]
|
J. J. Kiladjian, “The Spectrum of JAK2-Positive Myeloproliferative Neoplasms,” HEMATOLOGY American Society of Hematology Education Program, Vol. 2012, No. 1, 2012, pp. 561-566.
|
[9]
|
S. Y. Kristinsson, O. Landgren, J. Samuelsson, M. Bjorkolm and L. R. Goldin, “Autoimmunity and the Risk of Myeloproliferative Neoplasms,” Haematologica, Vol. 95, No. 7, 2010, pp. 1216-1220. http://dx.doi.org/10.3324/haematol.2009.020412
|
[10]
|
A. V. Jones and N. C. P. Cross, “No Association between Myeloproliferative Neoplasms and the Crohn’s Disease-Associated STAT3 Predisposition SNP rs744166,” Haematologica, Vol. 95, No. 7, 2010, pp. 1226-1227.
|
[11]
|
J. C. Barrett, S. Hansoul, D. L. Nicolae, J. H. Cho, R. H. Duerr, J. D. Rioux, et al., “Genomewide Association Defines More Than 30 Distinct Susceptibility Loci for Crohn’s Disease,” Nature Genetics, Vol. 40, No. 8, 2008, pp. 955-962. http://dx.doi.org/10.1038/ng.175
|
[12]
|
K. Wang, H. Zhang, S. Kugathasan, V. Annese, J. P. Bradfield, R. K. Russell, et al., “Diverse Genome-Wide Association Studies Associate the IL12/IL23 Pathway with Crohn Disease,” The American Journal of Human Genetics, Vol. 84, No. 3, 2009, pp. 399-405. http://dx.doi.org/10.1016/j.ajhg.2009.01.026
|
[13]
|
A. V. Jones, A. Chase, R. T. Silver, D. Oscier, K. Zoi, Y. L. Wang, et al., “JAK2 Haplotype Is a Major Risk Factor for the Development of Myeloproliferative Neoplasms,” Nature Genetics, Vol. 41, No. 4, 2009, pp. 446-449. http://dx.doi.org/10.1038/ng.334
|
[14]
|
D. Olcaydu, A. Harutyunyan, R. Jager, T. Berg, B. Gisslinger, I. Pabinger, et al., “A Common JAK2 Haplotype Confers Susceptibility to Myeloproliferative Neoplasms,” Nature Genetics, Vol. 41, No. 4, 2009, pp. 450-454. http://dx.doi.org/10.1038/ng.341
|
[15]
|
O. Kilpivaara, S. Mukherjee, A. M. Schram, M. Wadleigh, A. Mullally, B. L. Ebert, et al., “A Germline JAK2 SNP Is Associated with Predisposition to the Development of JAK2(V617F)-Positive Myeloproliferative Neoplasms,” Nature Genetics, Vol. 41, No. 4, 2009, pp. 455-459. http://dx.doi.org/10.1038/ng.342
|
[16]
|
S. Brand, “Crohn’s Disease: Th1, Th17 or Both? The Change of a Paradigm: New Immunological and Genetic Insights Implicate Th17 Cells in the Pathogenesis of Crohn’s Disease,” Gut, Vol. 58, No. 8, 2009, pp. 1152-1167. http://dx.doi.org/10.1136/gut.2008.163667
|
[17]
|
G. Finazzi, X. T. Gregg, T. Barbui and J. T. Prchal, “Idiopathic Erythrocytosis and Other Non-Clonal Polycythemias,” Best Practice & Research: Clinical Haematology, Vol. 19, No. 3, 2006, pp. 471-482. http://dx.doi.org/10.1016/j.beha.2005.07.006
|
[18]
|
J. L. Spivak and R. T. Silver, “The Revised World Health Organization Diagnostic Criteria for Polycythemia Vera, Essential Thrombocytosis, and Primary Myelofibrosis: An Alternative Proposal,” Blood, Vol. 112, No. 2, 2008, pp. 231-239. http://dx.doi.org/10.1182/blood-2007-12-128454
|
[19]
|
R. T. Silver, W. Chow, A. Orazi, S. P. Arles and S. J. Goldsmith, “Evaluation of WHO Criteria for Diagnosis of Polycythemia Vera: A Prospective Analysis,” Blood, Vol. 122, No. 11, 2013, pp. 1881-1886. http://dx.doi.org/10.1182/blood-2013-06-508416
|
[20]
|
G. Bergamaschi, A. Di Sabatino, R. Albertini, S. Ardizzone, P. Biancheri, E. Bonetti, et al., “Prevalence and Pathogenesis of Anemia in Inflammatory Bowel Disease. Influence of Anti-Tumor Necrosis Factor-Alpha Treatment,” Haematologica, Vol. 95, No. 1, 2010, pp. 199-205. http://dx.doi.org/10.3324/haematol.2009.009985
|
[21]
|
H. Reikvam and R. V. Tiu, “Venous Thromboembolism in Patients with Essential Thrombocythemia and Polycythemia Vera,” Leukemia, Vol. 26, No. 4, 2012, pp. 563-571. http://dx.doi.org/10.1038/leu.2011.314
|
[22]
|
O. Karimi, J. B. Crusius, C. Coucoutsi, R. Heijmans, A. M. Sambuelli, A. S. Pena, et al., “JAK2 V617F Mutation Is Not Involved in Thromboembolism in IBD,” Inflammatory Bowel Diseases, Vol. 14, No. 11, 2008, pp. 1606-1607. http://dx.doi.org/10.1002/ibd.20471
|
[23]
|
S. Verstovsek, R. A. Mesa, J. Gotlib, R. S. Levy, V. Gupta, J. F. DiPersio, et al., “A Double-Blind, Placebo Controlled Trial of Ruxolitinib for Myelofibrosis,” New England Journal of Medicine, Vol. 366, No. 9, 2012, pp. 799-807. http://dx.doi.org/10.1056/NEJMoa1110557
|
[24]
|
S. Verstovsek, “Therapeutic Potential of JAK2 Inhibitors,” Hematology, Vol. 2009, No. 1, 2009, pp. 636-642. http://dx.doi.org/10.1182/asheducation-2009.1.636
|
[25]
|
W. J. Sandborn, S. Ghosh, J. Panes, I. Vranic, C. Su, S. Rousell, et al., “Tofacitinib, an oral Janus Kinase Inhibitor, in Active Ulcerative Colitis,” New England Journal of Medicine, Vol. 367, No. 7, 2012, pp. 616-624. http://dx.doi.org/10.1056/NEJMoa1112168
|